Industry Expertise-arkiv - Page 2 of 4 - Biosector Ltd.

Editorial illustration showing complex healthcare data, regulatory, and localization inputs being streamlined through a Japan-themed gateway into clear eCOA/ePRO digital tools used by a doctor and patient.

by Stefan Sandström

Bringing eCOA and ePRO Solutions to Japan? What you Need to Get Right!

Japan is one of the world’s most demanding healthcare markets. It is also one of the […]

0

by Stefan Sandström

Infographic: Organoids and Organs-On-Chips

0

by Stefan Sandström

Takeda’s Savings Spree: What the Restructuring Really Means Now

Takeda’s savings programme is no longer an abstract investor slide. It has moved from corporate language […]

0

by Stefan Sandström

Takeda’s JPY 200 Billion Pivot: Welcome to Takeda’s New Launch Machine

The JPY 200 billion savings target currently dominating Takeda’s internal dialogue isn’t just a number on […]

1

by Stefan Sandström

Where the Organoid Field Stands Today

0

by Stefan Sandström

Infographic: Why CNS is the next Battleground for Organoids

0

Wide Biosector infographic showing five human-relevant model systems in drug discovery: spheroids, organoids, assembloids, organ-on-a-chip, and multi-organ systems, arranged from lower complexity to stronger translational insight.

by Stefan Sandström

Organoids, Organs-on-Chips, and the End of Lazy Translation

This article is a run-through of organoids and organs-on-chips in drug discovery! Drug discovery has a […]

0

Illustration of a company at a crossroads choosing among three market access routes into Japan: Own MAH, 3rd party DMAH, or Japanese partner as MAH, shown as three numbered roads leading toward a Tokyo cityscape.

by Stefan Sandström

MAH, DMAH, or a Japanese Partner: A Strategic Choice You Need to Make Before Entering Japan

Entering Japan is not only about regulatory approval, launch planning, and commercial ambition. One of the […]

0

Illustration of the supply chain for targeted alpha therapy in Japan using Astatine-211. The graphic shows domestic cyclotron production, GMP radiochemistry and automated purification, a national site network strategy, time-critical logistics across Japan due to the 7.2-hour half-life, and outpatient administration of the radiopharmaceutical.

by Stefan Sandström

Targeted Alpha Therapy in Japan: why Domestic ²¹¹At Supply Matters for Scale

Radioligand therapy is now a board-level topic in Japan, not because the science is new, but […]

0

Abstract wide illustration showing Japan drug pricing from listing to post-launch revisions, using blue shapes on a sand background with red trigger markers.

by Stefan Sandström

December 15, 2025

Japan FY2026 Drug Pricing Reform Draft: What Changes at Listing, What Tightens After Launch

On December 12, 2025, Japan’s Ministry of Health, Labour and Welfare (MHLW) tabled a draft outline […]

0